BiotechTube
Home/Pipeline/TDP-43 Program

TDP-43 Program

Amyotrophic Lateral Sclerosis (ALS)

DiscoveryActive

Key Facts

Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Discovery
Status
Active
Company
Korro Bio

About Korro Bio

Korro Bio is developing transformative genetic medicines by co-opting the body's natural RNA editing machinery to correct disease-causing mutations or modulate protein function. The company's OPERA® platform and first-generation CHORD™ oligonucleotides are designed for high specificity, transient activity, and delivery via clinically validated methods like GalNAc. With a pipeline focused on liver and CNS diseases, Korro is advancing multiple wholly-owned programs, recently securing an $85 million private placement to fund its development efforts.

View full company profile

Therapeutic Areas

Metabolic DisordersNeurologyRare DiseasesHepatology

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

DrugCompanyPhase
Utreloxastat (PTC857)PTC TherapeuticsPhase 2
SAR443820/DNL788Denali TherapeuticsPhase 2
PegcetacoplanApellis PharmaceuticalsPhase 2
RELYVRIO/ALBRIOZA (AMX0035)Amylyx PharmaceuticalsApproved/Commercial
AMX0035Amylyx PharmaceuticalsPhase 3
AMX0114Amylyx PharmaceuticalsPhase 1
Taldefgrobep alfaBiohavenPhase 2/3
AMT-162uniQurePreclinical
AAV-UPF1MeiraGTxPreclinical
TegoprubartEledon PharmaceuticalsPhase 2
Intranasal ForalumabTiziana Life SciencesPhase 2
COYA 302Coya TherapeuticsPhase 2